Marth to Become New CEO of Teva North America

PharmaManufacturing.com
01/15/2008

Teva Pharmaceutical Industries Ltd., Jerusalem, Israel, announced Jan. 10 that George S. Barrett, CEO of Teva North America and corporate executive VP, Global Pharmaceutical Markets, has resigned from the Company and that William S. Marth, currently President and CEO of Teva USA, will replace Barrett and assume the additional role of CEO of Teva North America effective immediately.

Barrett, who is leaving to become Vice Chairman of Cardinal Health and CEO of its Healthcare Supply Chain Services Sector, will remain with Teva through the end of January 2008 to assist in the transition.

Marth, who has 30 years experience in the pharmaceutical industry and close to a decade with Teva, will be responsible for North America, including the U.S. Marth has run the U.S. generics business where he has handled much of the day-to-day commercial activities since his appointment as EVP in 2002 and has been president and chief executive officer of Teva USA since 2005.

He has overseen a number of significant product launches, most notably the December launch of generic Protonix, and two of the largest launches in the history of U.S. generics, Simvastatin and Pravastatin in 2006. Mr. Marth, will continue to be based in Teva's North American headquarters in North Wales, Pa. and will report directly to Teva President and CEO Shlomo Yanai.

Marth assumed the position of president and CEO of Teva USA in 2005. Prior to that, he served as executive vice president and as vice president of sales and marketing of Teva USA. Before joining the Company, Marth served in various leadership positions with the Apothecon Division of Bristol-Myers Squibb.